Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Filings indexed 449 across all filing types
Latest filing 2024-04-15 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a compliance certificate issued under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It is a confirmation certificate from the Registrar and Share Transfer Agent regarding dematerialization compliance for the quarter ended 31-Mar-2024. The document is a regulatory compliance certificate and does not contain financial statements, management discussion, or detailed financial data. It is also relatively short (4217 characters) and serves as a formal attestation of compliance rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory compliance documents and certifications that do not fit other specific categories.
2024-04-15 English
Resignation of Independent director
Regulatory Filings
2024-04-12 English
Resignation
Board/Management Information Classification · 100% confidence The document is an official intimation to stock exchanges regarding the resignation of an Independent Director, Mr. Mudit Tandon, from the company Orchid Pharma Limited. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and includes annexures with details about the resignation and confirmations from the director. The content is focused on management change and does not contain financial data, audit information, or report publication details. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4428 characters, which is consistent with a detailed announcement rather than a full report.
2024-04-12 English
Updates
Regulatory Filings Classification · 95% confidence The document is an explanation letter regarding a delay in filing an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It references a previous intimation dated December 14, 2023, about the resignation of the Company Secretary & Compliance officer. The document is short (2265 characters) and serves as a regulatory update or explanation rather than a full report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report itself but a regulatory communication explaining a delay in a prior filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2024-04-06 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice from Orchid Pharma Limited addressed to stock exchanges regarding the closure of the trading window for insiders due to upcoming audited financial results for the quarter and financial year ending March 31, 2024. It references SEBI regulations on insider trading and informs about the trading window closure period starting April 1, 2024, until 48 hours after the declaration of audited results. The document does not contain any financial data or results itself, nor does it include the audited financial results report. It is a regulatory announcement related to compliance and insider trading restrictions ahead of financial results publication. The document length is short (2752 characters) and serves as an intimation rather than a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice.
2024-03-30 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice (1828 characters) addressed to stock exchanges referencing a prior disclosure and informing about the filing of an appeal against a tax order. It cites Regulation 30 of SEBI Listing Obligations, which pertains to continuous disclosure requirements. The content is an intimation or update about a legal/tax matter, not a full report or financial statement. It does not contain financial data or detailed report content. It is an announcement of a regulatory event or filing, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2024-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.